Trodelvy™ (sacituzumab govitecan-hziy)(Intravenous)Document Number: IC-0532 Last Review Date: 01/01/2021 Date of Origin: 06/02/2020 Dates Reviewed: 06/2020, 09/2020, 01/2021 I.Length of Authorization Coverage will be provided for six months and may be renewed.II.Dosing Limits A....
Camptosar [package insert], Pharmacia & Upjohn Co., New York, NY (2020) Google Scholar 44 H.S. Rugo, S.M. Tolaney, D. Loirat, et al. Impact of UGT1A1 status on the safety profile of sacituzumab govitecan in the phase 3 ASCENT study in patients with metastatic triple-negative ...
Sacituzumab govitecan (SG) is an antibody-drug conjugate (ADC) composed of a humanized trophoblast cell-surface antigen-2 (Trop-2) antibody coupled to an SN-38 payload, the active metabolite of the topoisomerase 1 inhibitor irinotecan, via a proprietary, hydrolyzable linker15. SG is a Trop–...